Catalent puts $20M into nasal drug delivery

Catalent Pharma Solutions is again expanding its manufacturing operations in North Carolina, this time to build new capacity for inhalation drugs. The company said it will invest about $20 million in expanding pressurized metered dose inhaler clinical and commercial supply capabilities as well as making some other enhancements to the facility in Research Triangle Park, NC. Scott Houlton, Catalent's president of development and clinical services, said the investment allows for scalable processes for microdosing inhalation powder formulations and covers the recent commissioning of a new nasal filling suite. "Pulmonary and nasal represents the second-largest drug delivery market by delivery route," he said. In June, the company completed renovation of a 3,300-square-foot aseptic fill-finish manufacturing suite at the plant. Release | More